Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of neuropsychiatric therapeutics. Its clinical stage drug candidate, ganaxolone, is a novel synthetic small molecule that is an analog of allopregnanolone, a natural occurring neurosteriod produced by the human body, which modulates gamma-aminobutyric acid a neurotransmitter in the brain. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
Market Cap | 203.149 Million | Shares Outstanding | 37.003 Million | Avg 30-day Volume | 239.881 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -2.29 |
Price to Revenue | 28.3845 | Debt to Equity | 0.763 | EBITDA | -95.37 Million |
Price to Book Value | 8.8557 | Operating Margin | -631.6781 | Enterprise Value | 357.744 Million |
Current Ratio | 3.246 | EPS Growth | 0.039 | Quick Ratio | 3.095 |
1 Yr BETA | 1.7459 | 52-week High/Low | 19.83 / 4.19 | Profit Margin | -643.7015 |
Operating Cash Flow Growth | 8.9227 | Altman Z-Score | -2.4772 | Free Cash Flow to Firm | -42.004 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
15,687 | 2022-02-04 | 1 | |
|
18,817 | 2022-02-04 | 1 | |
MANNING MARTHA E VP GEN COUNSEL AND CORP SEC. |
|
70,767 | 2022-02-04 | 1 |
|
26,250 | 2022-02-04 | 1 | |
|
15,125 | 2022-02-04 | 1 | |
|
15,819 | 2022-02-04 | 1 | |
BRAUNSTEIN SCOTT CHIEF EXECUTIVE OFFICER |
|
260,950 | 2022-02-04 | 1 |
|
15,125 | 2022-02-04 | 3 | |
HULIHAN JOSEPH CHIEF MEDICAL OFFICER |
|
94,325 | 2022-02-04 | 1 |
|
15,125 | 2022-02-04 | 1 | |
|
15,125 | 2022-02-04 | 1 | |
PFANSTIEL STEVEN CHIEF FINANCIAL OFFICER |
|
91,025 | 2022-02-04 | 1 |
SMITH EDWARD F FORMER VP, CFO & TREASURER |
|
No longer subject to file | 2021-03-09 | 0 |
|
0 | 2021-01-15 | 0 | |
LORIANNE MASUOKA K. CHIEF MEDICAL OFFICER |
|
0 | 2019-08-21 | 0 |
|
No longer subject to file | 2019-03-18 | 0 | |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC BAIN CAPITAL LIFE SCIENCES PARTNERS, LP BAIN CAPITAL LIFE SCIENCES FUND, L.P. |
|
No longer subject to file | 2017-12-15 | 0 |
|
0 | 2017-01-17 | 0 | |
SOFINNOVA VENTURE PARTNERS VI L P SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG SOFINNOVA VENTURE AFFILIATES VI LP |
|
No longer subject to file | 2016-10-20 | 0 |
|
No longer subject to file | 2016-08-05 | 0 | |
|
0 | 2016-08-03 | 0 | |
PATRONEVA ALBENA CHIEF MEDICAL OFFICER |
|
0 | 2016-08-03 | 0 |
|
2,500,948 | 2015-09-24 | 0 | |
FARFEL GAIL M CHIEF CLINICAL DEV & REG OFFIC |
|
0 | 2015-04-21 | 0 |
|
42,550 | 2015-01-01 | 0 | |
|
0 | 2014-09-30 | 0 | |
|
2,476,886 | 2014-08-05 | 0 | |
|
17,000 | 2014-08-05 | 0 | |
|
42,550 | 2014-07-31 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 22:15:04 UTC | -0.2321 | 1.0521 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 21:45:04 UTC | -0.229 | 1.049 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 21:15:03 UTC | -0.229 | 1.049 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 20:45:03 UTC | -0.2085 | 1.0285 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 20:15:05 UTC | -0.2085 | 1.0285 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 19:45:04 UTC | -0.2085 | 1.0285 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 19:15:03 UTC | -0.2085 | 1.0285 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 18:45:03 UTC | -0.195 | 1.015 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 18:15:03 UTC | -0.195 | 1.015 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 17:45:03 UTC | -0.195 | 1.015 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 17:15:03 UTC | -0.195 | 1.015 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 16:45:04 UTC | 0.0304 | 0.7896 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 16:15:03 UTC | 0.0304 | 0.7896 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 15:45:03 UTC | 0.0304 | 0.7896 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 15:15:03 UTC | 0.0304 | 0.7896 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 14:45:03 UTC | -0.0013 | 0.8213 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 14:15:03 UTC | -0.0013 | 0.8213 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 13:45:03 UTC | -0.0013 | 0.8213 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 13:15:03 UTC | -0.0013 | 0.8213 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2022-05-17 12:45:03 UTC | -0.0013 | 0.8213 | 650000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund | MRNS | -1779.0 shares, $-2739.66 | 2019-09-30 | N-PORT |
Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund | MRNS | -1400.0 shares, $-15932.0 | 2021-09-30 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | MRNS | -375.0 shares, $-4455.0 | 2021-12-31 | N-PORT |